Nanomedicine therapeutic approaches to overcome cancer drug resistance  by Markman, Janet L. et al.
Advanced Drug Delivery Reviews 65 (2013) 1866–1879
Contents lists available at ScienceDirect
Advanced Drug Delivery Reviews
j ourna l homepage: www.e lsev ie r .com/ locate /addrNanomedicine therapeutic approaches to overcome cancer
drug resistance☆☆
Janet L. Markman 1, Arthur Rekechenetskiy 1, Eggehard Holler 1,2,3, Julia Y. Ljubimova ⁎,1,2
1 Nanomedicine Research Center, Department of Neurosurgery at Cedars-Sinai Medical Center, Los Angeles, CA, United States
2 Arrogene, Inc., Santa Monica, CA, United States
3 Department of Biology and Preclinics at Regensburg University, Regensburg, GermanyAbbreviations: AML, acute myeloid leukemia; CAM-D
nervous system; CSC, cancer stem cell; EGFR, epidermal
H2N-Leu-Leu-Leu-OH; IGF-1R, insulin-like growth factor 1
factor κB; NSCLC, non-small cell lung cancer; PDGFR-β, pla
derived factor 1; siRNA, short interfering RNA; TAT, trans
TNFα, tumor necrosis factor α.
☆☆ This review is part of the Advanced Drug Delivery Rev
⁎ Corresponding author at: Department of Neurosurge
90048, United States. Tel.: +1 310 423 0834; fax: +1 310
E-mail address: ljubimovaj@cshs.org (J.Y. Ljubimova)
0169-409X © 2013 The Authors. Published by Elsevier B
http://dx.doi.org/10.1016/j.addr.2013.09.019a b s t r a c ta r t i c l e i n f oArticle history:
Accepted 30 September 2013
Available online 10 October 2013
Keywords:
Nanobiopolymers
Nanodrug
Drug delivery
Tumor multidrug resistanceNanomedicine is an emerging form of therapy that focuses on alternative drug delivery and improvement of the
treatment efﬁcacy while reducing detrimental side effects to normal tissues. Cancer drug resistance is a
complicated process that involves multiple mechanisms. Here we discuss the major forms of drug resistance
and the new possibilities that nanomedicines offer to overcome these treatment obstacles. Novel nanomedicines
that have a high ability for ﬂexible, fast drug design and production based on tumor genetic proﬁles can be created
making drug selection for personal patient treatment much more intensive and effective. This review aims to
demonstrate the advantage of the young medical science ﬁeld, nanomedicine, for overcoming cancer drug
resistance.With the advanced design and alternativemechanisms of drug delivery known for different nanodrugs
including liposomes, polymer conjugates, micelles, dendrimers, carbon-based, and metallic nanoparticles,
overcoming various forms ofmulti-drug resistance looks promising and opens new horizons for cancer treatment.
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Resistance to antineoplastic chemotherapy is a combined
characteristic of the speciﬁc drug, the speciﬁc tumor, and the
speciﬁc host whereby the drug is ineffective in controlling the
tumor without excessive toxicity.
The problem for themedical oncologist is not simply toﬁnd an agent
that is cytotoxic but to ﬁnd one that selectively kills neoplastic cells
while preserving the essential host cells and their functions. Were it
not for the problem of resistance of human cancer to antineoplastic
agents or, conversely, the lack of selectivity of those agents, cancer
chemotherapy would have been similar to antibacterial chemotherapy
in which complete eradication of infection is regularly observed.
Natural (inherited) or acquired resistance is one of themain problems
associated with cancer treatment. Natural resistance refers to the initial
unresponsiveness of a tumor to a given drug, and acquired resistance
refers to the unresponsiveness that emerges after initial successful
treatment.
There are three basic categories of resistance to chemotherapy:
kinetic, biochemical, and pharmacologic. Cell kinetics and resistance is
a particular problem with many human tumors because certain cells
are in a plateau growth phase with a small growth fraction. Strategies
to overcome resistance due to cell kinetics include: reduction of the
bulk of tumors with surgery or radiotherapy; using combinations to
include drugs that affect resting populations (G0 cells); and scheduling
of drugs to prevent phase escape or to synchronize cell populations
and increase tumor cell elimination. How cells become resistant
biochemically is only partially understood. The major mechanisms of
biochemical resistance include the inability of a tumor to convert the
drug to its active form, the inactivation of a drug, and the upregulation
of the tumor enzymatic repair systems that counteract the tumoricidal
action. Cells in this resistance category can decrease drug uptake,
increase efﬂux, change the levels or structure of the intracellular target,
reduce intracellular activation, increase inactivation of the drug, or
increase the rate of repair of damaged DNA. Another example is
multidrug resistance (MDR), also called pleiotropic drug resistance,
which is a phenomenon whereby treatment with one agent confers
resistance not only to that drug andother(s) of its class but also to several
other unrelated agents. Pharmaceutical resistance can result from poor
tumor blood supply, poor or erratic absorption, increased excretion or
catabolism, and drug interactions, which all lead to inadequate blood
levels of the drug. One other example of pharmacologic resistance is
poor transport of agents into certain body tissues and tumor cells. For
instance, tumors of the central nervous system (CNS) or ones that
metastasize there should be treated with drugs that achieve effective
antitumor concentration in the brain tissue and are also effective against
the tumor cell type being treated.Novel nanomedicines offering ﬂexible and fast drug design and
production based on tumor genetic proﬁles can be created making
drug selection for personalized patient treatment much more rational
and effective. This review aims to demonstrate the advantages of
nanomedicine in overcoming cancer drug resistance.
2. Classes of nanodrugs used to treat cancer and their current
clinical status
Nanomedicines are being investigated for their use in anticancer
therapies to improve drug delivery, increase the efﬁcacy of treatment,
reduce side effects, and overcome drug resistance. The number of
studies published under the research topics of “nanomedicine,”
“nanoscience,” and “nanotechnology” has increased exponentially
over the past decade with a slight decline in 2012, as shown in Fig. 1.
As more nanostructures were discovered and their potentials were
better understood, the number of publications increased and reached
its peak in 2011. Currently, the knowledge base of nanoparticles is still
expanding with an emphasis on safety and efﬁcacy.
2.1. Lipid-based nanoparticles (liposomes)
Liposomes, as shown in Fig. 2A, are lipid based vesicles that have the
ability to carry payloads in either an aqueous compartment or
embedded in the lipid bilayer. The delivery of these liposomes to cancer
cells often relies on passive targeting and is based on the enhanced
permeability and retention (EPR) effect, for which a leaky tumor
vasculature is necessary [1]. A number of liposomes with the addition
of targeting ligands, such as the mAb 2C5 with Doxorubicin (Doxil®)
[2] and an anti-HER2 mAb with Paclitaxel [3], are in the preclinical
phase, whereas others are already undergoing clinical trials. Advances
to liposome design have also been made with the addition of
polyethylene glycol (PEG, known as stealth liposomes), which increases
circulation time, as well as strategies for a triggered release of the drug
once internalized, such as hyperthermia, as is used in ThermoDox®,
which is currently in Phase III trials [1,4,5].
2.2. Polymer-based nanoparticles and micelles
Polymeric nanoparticles, as shown in Fig. 2B, can either covalently
attach to or encapsulate therapeutic payloads. Biodegradable synthetic
and/or natural polymers are used. Through self-assembly after mixing
the drug with the polymers, capsules may be formed spontaneously
(micelles, Fig. 2C) or by emulsion techniques as nanosized droplets.
These nanospheres contain a solid core that is ideal for hydrophobic
drugs, are highly stable, have a relatively uniform size, and are capable
of controlled drug release. For water-soluble polymers, drugs can be
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Fig. 1. The number of references under the research topics of “nanomedicine,” “nanoscience,” and “nanotechnology” from 1996 to 2012. The number of publications peaked in 2011 with
7279 and saw a slight decline in 2012 with 7011 publications.
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to normal tissues [6–9]. Polymers have been reﬁned with the addition
of PEG to avoid opsonization and increase circulation time, the use
of targeting ligands, and theuse of pH-sensitive or hypothermic polymer
conjugates. Currently, two polymers, polylactide (PLA) andpoly(lactide-
co-glycolide) (PLGA), are polymeric biodegradable nanoplatforms that
are used for synthesis of FDA-approved nanomedicines, whereas many
others are undergoing clinical trials [7].
2.3. Dendrimers
Dendrimers are well-deﬁned globular structures of multi-branched
polymers that are characterized by a central core, branches of repeating
units, and an outer layer of multivalent functional groups, as shown inDrug Targeting Agent Ima
D) Dendrimer E) Carbon Nan
B) Polymer-CoA) Liposome
Fig. 2. An illustrative representation of different classes of third-generation multiple functiona
imaging moieties.Fig. 2D. These functional groups can electrostatically interact with
charged polar molecules, whereas the hydrophobic inner cavities can
encapsulate uncharged, non-polar molecules through a number of
interactions. The outer functional groups also allow for controlled
delivery of the drug by modiﬁcations that only release in a certain
pH or when encountered by speciﬁc enzymes; targeting molecules,
such as the RGD peptide or mAbs are also used. Further, covalent
attachment of hydrophobic drugs such as Doxorubicin and Paclitaxel
is frequently employed [6,7,10]. Dendrimers, such as poly(glutamic
acid)-b-poly(phenylalanine) copolymers, can also be self-assembled
into micelles to deliver drugs in their core. Multiple clinical trials are
ongoing using amphiphilic diblock copolymer forming micelles to
deliver Paclitaxel to treat breast, non-small cell lung cancer, and
advanced pancreatic cancer [11].ging Agent Linker
otube
C) Micelle 
F) Gold Nanoparticle
njugate
l nanodrugs and their potential moieties for targeting, PEGylated for resistance and with
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Carbon nanotubes have the ability to enter cells using “needle-like
penetration” and deliver molecules into the cytoplasm. These
nanoparticles are equipped with a large surface area providing for a
number of attachment sites for potential targeting ligands, as well as
an internal cavity that can contain either therapeutic or diagnostic
agents, as shown in Fig. 2E. These carbon nanotubes also have electrical
and thermal conductivity, whichmay prove to be useful in future cancer
therapy applications such as thermal ablations. The length and diameter
of these nanotubes can be crucial for avoiding an inﬂammogenic effect,
making smaller and thicker nanotubes more desirable and a focus on
biodegradability necessary. Current approaches to nanotubes include
the incorporation of drugs such as Doxorubicin and Paclitaxel, nucleic
acids including antisense oligonucleotides and short interfering RNAs
(siRNAs), [12] and the use of nanotubes as contrast agents for imaging.
To our knowledge, no clinical trials have begun using carbon nanotubes
for the treatment or diagnosis of cancer, mainly because of toxicity
concerns and their similarity to asbestos ﬁbers [7].2.5. Metallic and magnetic nanoparticles
Gold nanoparticles, as shown in Fig. 2F, can be used to deliver small
molecules such as proteins, DNA, or RNA. The gold core is considered to
be non-toxic and the therapeutic payload can be forced to be released
from the conjugate due to their photo-physical properties. Drugs can
easily be attached through ionic or covalent bonds, or through adhesion.
Like for many nanodrugs, PEG can be attached to the surface of metallic
nanoparticles to increase stability and circulation time, in addition to
other targeting agents [11]. Sodium citrate can also be used as a
reducing agent for gold formation, and a stabilizer to avoid aggregation
during synthesis [13]. Currently, one phase I clinical trial using tumor
necrosis factor α (TNFα) bound to colloidal gold is ongoing to treat
advanced solid tumors such as sarcomas and melanomas [14].
Superparamagnetic iron oxide (Fe3O4) nanoparticles are also under
development and require the use of local hyperthermia or oscillation
strategies to deliver conjugated drugs. Magnetic ﬁelds can also be
used to guide the drug to the intended target area within the body.
Unfortunately, their potential clinical use is not presently understood
due to the acute in vivo toxicity [15]. Moreover, this class of particles is
being thoroughly investigated for their use in imaging and theranostics
(diagnostics and therapy), but this is beyond the scope of the review.ATP ADP
ABC transporters
Phospholipid bilayer
Chemotherapeutic drug
Fig. 3. Upregulation of ABC transporters on cancer cell membranes effectively removes
chemotherapeutic drugs and cytotoxic agents as a means of drug resistance.3. Mechanisms of drug resistance
3.1. Multidrug resistance mechanisms
Multidrug resistance (MDR) is the term used to describe the
resistance of cancer to related and unrelated classes of chemotherapeutic
drugs and is currently one of the biggest challenges to overcome. Initially,
patientsmay have either a partial or complete response to the ﬁrst line of
treatment but eventually exhibit cancer progression or recurrence. With
repeated treatment, tumors often become resistant not only to the
speciﬁc chemotherapeutic agent being employed, but cross-resistant to
both similar and structurally unrelated classes of cytotoxic drugs
[16–18].
3.1.1. Efﬂux pump-mediated MDR
The increased activity of drug efﬂux occurs primarily through the
ATP-binding cassette (ABC) superfamily. ABC transport molecules are
typically expressed on the plasma membrane and on the membrane
of cellular vesicles and are used to extrude toxins and other foreign
substances from the cell. The ABC transporters are transmembrane
proteins that use the energy from ATP hydrolysis to shuttle substrates
across the membrane. Thirteen of the 48 known ABC transporters
contribute to MDR [16]. The ﬁrst discovery was the mdr 1 gene that
encodes the high molecular weight P-glycoprotein (P-gp/ABCB1),
which is ampliﬁed in drug-resistant cells and leads to a decrease in
drug accumulation [19]. Other proteins including multidrug resistance
proteins (MRPs/ABCC) and breast cancer resistance protein (BCRP/
ABCG2) are also upregulated in cancer cells and effectively remove
cytotoxic agents including Doxorubicin [20–23] and Paclitaxel [24–27]
greatly decreasing their concentration within tumor cells, as shown in
Fig. 3 [28].
3.1.2. Efﬂux pump-independent MDR
Additional mechanisms of MDR include decreased drug inﬂux,
activation of DNA repair, metabolic modiﬁcation and detoxiﬁcation,
and altered expression of apoptosis-associated proteins and tumor
suppressors, namely mutations in p53 [16]. Normal cells have several
repair mechanisms including base excision repair for single strand
breaks, homologous recombination and non-homologous end joining
repair for double strand breaks, and nucleotide excision repair for
mismatches, insertions, and deletions. These mechanisms are used to
prevent the transmission of damaged DNA and to avoid malignant
transformation [29]. If any of these mechanisms fail, apoptosis is
activated to eliminate the damaged cells. However, DNA damage
response mutants predispose cells to becoming cancerous and affect
response to chemotherapy. Cell cycle arrest does not occur when
mutations, chromosomal rearrangements, and epigenetic changes are
present, even when induced by anticancer therapies that induce DNA
damage to cause cytotoxicity [30]. Further, the anti-apoptotic, pro-
survival regulator Bcl-2 [31] and nuclear factor kappa B (NF-κB), a
transcription factor that controls genes that suppress apoptotic
responses [32], are frequently overexpressed in cancer cells and lead
to increased survival.
3.2. Tumor cell heterogeneity, clonal selection and expansion as a potential
source of drug resistance
It is accepted at the current stage of cancer biology that tumors at the
same clinical grade and histological status are genetically heterogeneous
and contain subclonal populations [33]. A large-scale whole-exome
sequencing study of 160 chronic lymphocytic leukemia (CLL) patients
revealed 20 mutated genes and 5 cytogenetic alterations as driver
mutations that spanned 7 core signaling pathways. Clonal mutations
(drivers) were found in the majority of tumor cells and represent an
early event, whereas subclonal mutations were only found in a small
number of leukemic cells, representing a later transformation. In patients
1870 J.L. Markman et al. / Advanced Drug Delivery Reviews 65 (2013) 1866–1879who had undergone chemotherapy, a signiﬁcantly higher number of
subclonal (but not clonal) mutations were found indicating that
subclonal mutations are increased with treatment. This may be due to
the removal of dominant clones by cytotoxic treatment and a subsequent
expansion of subclones, as shown in Fig. 4A. Two time points of whole-
exome sequencing for 18 of these patients was also performed. In 10 of
the 12 patients that underwent treatment between time points, clonal
expansion was evident. Conversely, 5 of the 6 untreated individuals
remained at equilibrium between populations over several years. For
the treated patients that did exhibit subclonal evolution, the somatic
driver mutations that expanded were detectable at the ﬁrst time point
and thus could potentially be anticipated in association with treatment
[34]. The emergence of resistant subclones following treatment may
allow for tumor expansion and recurrence. The ability to target multiple
clonal and subclonal mutations simultaneously is a promising strategy
for nanomedicine due to the number of attachment sites present
on certain classes of nanoplatforms, which are used in nanodrug
development.
3.3. Cancer stem cells (CSCs) and drug resistance
Cancer stem cells, also known as tumor initiating cells, are cells that
have the capacity to self-renew and to give rise to the heterogeneous
lineages that are found within a tumor [35]. Evidence for cancer stem
cells dates back to 1971 when it was shown that only 1 in 100 to 1 in
10,000 mouse myeloma cells were able to form colonies [36]. This was
conﬁrmed 6 years later in humans when only 1 in 1000 to 1 in 5000
lung cancer, ovarian cancer, or neuroblastoma cells formed colonies in
soft agar [37]. However, a fundamental question on whether all cancer
cells had a low probability to behave as stem cells or if only a small
subset had the ability to proliferate rapidly and form tumors remained
[38]. One essential study to answer this question was performed in a
group of acute myeloid leukemia (AML) patients in 1997. Dick et al.
showed that only a very small subset of cells that were CD34+CD38−
had the ability to cause AML in NOD/SCID mice, indicating that
subpopulations of cells had differential abilities to proliferate and
transfer disease [39]. Tumor initiating cells were later isolated in breast
carcinomas, and itwas shown that only a subset of cells could be serially
passaged and gave rise to both phenotypically identical and diverse cells
consistent with those found in the initial tumor [40]. Cancer stem cells
have also been isolated from medulloblastoma, glioblastoma [41],
ependymoma [42], colon cancer [43,44], chronic and acute myeloidPopulation 1
Population 2
Population 3
Population 4
A) Tumor heterogeneity B) T
       s
Fig. 4. Two alternate drug resistancemechanisms. A. A heterogeneous population of cancer cells
eliminatedwhile a subpopulation, Population 4, emerges as a dominant clone (bottom right). B.
left. After administration of treatment, only the resistant cancer stem cells are seen (top right
populations present before treatment (bottom right).leukemia [45], pancreatic cancer [46], and head and neck squamous
cell carcinomas [47]. However, the origins of these CSCs, i.e. from
normal stem cells versus progenitor cells, is still not clear and may
vary from tumor to tumor or by tumor type [48]. One key feature of
CSCs is the role that they play in resistance to therapy and recurrence.
Because chemotherapeutic drugs typically affect frequently dividing
cells, CSCs, which are primarily quiescent and have active DNA repair
mechanisms, are not harmed. They also express high levels of speciﬁc
ABC drug transporters, namely ABCB1, ABCG2, and ABCC1, which are
known MDR genes in tumor cells, allowing for increased survival.
Whereas chemotherapy may be effective against committed tumor
cells, the resistant CSCs may survive and repopulate the tumor with
self-renewing cells and variably differentiated offspring, as shown in
Fig. 4B [49]. The ability to eradicate these CSCs with speciﬁc drugs is
crucial to prevent tumor repopulation and recurrence.3.4. Activation of alternate receptors and pathways in cancer as a response
to treatment
Therapeutic approaches based on molecular pathways are currently
targeting commonly upregulated pathways in order to prevent
compensatory pathways. Small molecular inhibitors and monoclonal
antibodies show promise in clinical trials and during initial cancer
treatment, but resistance is inevitable. A number of intrinsic and
acquired resistance mechanisms have been well studied. The activation
of alternate receptors, such as c-met and insulin-like growth factor 1
receptor (IGF-1R), in response to anti-epidermal growth factor receptor
(EGFR) therapies, is a common adaptation that cancer cells exhibit.
The use of other tyrosine kinase receptors allows the cells to bypass
the effects of the drug and continue anti-apoptotic, proliferative
downstream signaling, in this case, the activation of the phospho-
inositide 3-kinase (PI3K) pathway. Antiangiogenic strategies based on
VEGFR modulation have also shown resistance through multiple
mechanisms. An initial response to anti-VEGF therapy often results in a
hypoxia-triggered upregulation of non-VEGF angiogenic factors, such
as those in the ﬁbroblast growth factor (FGF) family, and a recurrence
of angiogenesis [50]. Thus, drugs that only target one pathway can lead
to the reinforcement of alternate pathways that are beneﬁcial to
the tumor and may contribute to MDR. Designing nanomedicines that
can target multiple pathways at once is ideal for reducing this form of
MDR.Cancer Stem Cells
Population 1
Population 2
Population 3
umor heterogeneity with cancer 
tem cells
is shown in the top left. Following administration of treatment, Population 3 is completely
A heterogeneous population of cancer cells, including cancer stem cells, is shown in the top
). After time, the cancer stem cells are able to repopulate the tumor with all previous cell
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Intrinsic mutations have been shown to have a large impact on
response to therapy. Somatic mutations resulting in a gain-of-
function activation of the tyrosine kinase domain of EGFR in a cohort
of non-small cell lung cancer (NSCLC) were discovered in 35% of the
enrolled patients and were shown to signiﬁcantly impact response
rates to geﬁtinib (55%) [51]. In-frame deletions in exon 19 and single
missense mutations account for approximately 90% of the EGFR
mutations, and result in an increased sensitivity to both small
molecule inhibitors, geﬁtinib and erlotinib [52–54]. Nearly 70% of
patients with a mutation (found in 10–25% of all NSCLC patients)
respond to therapy compared to only a 10% response rate when no
mutations are present [55,56]. However, acquired resistance to
therapy is associated with a secondary mutation in exon 20 that
leads to substitution of methionine for threonine at position 790M
(T790M) in the kinase domain, preventing the binding of erlotinib
[57]. Subsequent studies of different patients with acquired T790M
mutations revealed that this mutation was not present in untreated
tumor samples. Further, the resistance was not found to be
associated with KRAS mutations that can cause primary resistance
and transfection of cells in vitro conferred resistance to geﬁtinib
and erlotinib in normally sensitive cells [58]. An acquired mutation,
S492R, in the EGFR ectodomain has also been identiﬁed in colorectal
cancer patients following treatment with cetuximab that prevents
the binding of the antibody. Interestingly, it does not affect the
binding ability of a different anti-EGFR mAb, panitumumab [59].
Together, these mutations, whether intrinsic or acquired, allow
these cancer cells to avoid the effects of cytotoxic agents and to
survive. Thus, nanodrugs designed to knockdown both wild-type
and mutated genes are necessary to overcome these compensatory
mechanisms. Antisense oligonucleotides attached to polymalic acid
biopolymer that block wild-type EGFR and mutated EGFRvIII
receptor synthesis have been successfully used to treat triple
negative breast cancer [60] employing a strategy based on acquired
mutations by the MDA-MB-468 breast cancer cell line.
3.6. Tumor microenvironment and its contribution to MDR
Solid tumors are found within a microenvironment that is
comprised of cancer cells and stromal cells (including ﬁbroblasts and
immune cells), embedded in an extracellular matrix. This stroma can
affect malignant transformation, plays a role in tumor cell invasion
andmetastasis, and has an impact on drug sensitivity. The tumor stroma
has an increased number of ﬁbroblasts (and also myoﬁbroblasts) that
synthesize growth factors, chemokines, and adhesion molecules. A
representative ﬁgure of the complexity of this microenvironment is
shown in Fig. 5. The interactions between the cancer cells and these
factors can affect the sensitivity of the cells to apoptosis and their
response to chemotherapy, and is known as cell adhesion-mediated
drug resistance (CAM-DR) [61]. Adhesion of myeloma cells to
ﬁbronectin throughβ1 integrins,whose activation is known to inﬂuence
apoptosis and cell growth, results in CAM-DR. The adhesion leads to a G1
arrest associated with increased p27kip1 expression and inhibition of
cyclin A and E kinase activity; disruption of this interaction returns the
tumor cells to a drug-sensitive state [62]. Tumor cells also form
polarized, three-dimensional structures through interactions with the
basement membrane and ligation of β4 integrins, which regulate
polarity and NF-κB activation. These cells become resistant to
apoptosis-inducing agents, likely due to the effects on NF-κB [63]. The
pH of the tumor microenvironment can also inﬂuence the effectiveness
of cytotoxic drugs and may inhibit the active transport of some
therapeutics [61,64]. The extracellular pH in tumors is acidic and the
intracellular pH is neutral to basic. Thus, weakly basic drugs, such as
Doxorubicin, are protonated and have reduced cellular uptake [65].
Weakly acidic drugs, such as cyclophosphamide, tend to concentrate inneutral extracellular space [66]. Drug distribution is also affected by
the composition and organization of the extracellular matrix [67].
Tumors with a well-organized collagen network prevent some high-
molecular weight drugs from penetrating when compared to a poorly
organized collagen structure [68]. Further, the tumormicroenvironment
can create hypoxic situations in which tumor tissue has a diminished
oxygen supply that can contribute to MDR [69]. These areas result
from abnormal angiogenesis or from the compression/closing of blood
vessels by cancer cells [70]. This reduced blood ﬂow may lower
concentrations of chemotherapeutics in hypoxic cells [71]. In addition,
hypoxia can lead to the activation of genes associatedwith angiogenesis,
survival, and glycolysis through the transcription factor hypoxia-
inducible factor 1 (HIF-1) and may contribute to a drug-resistant
phenotype [61,72]. HIF-1 transcriptional activity also enhances
metabolism, proliferation, invasion, and metastasis by the tumor cells.
These hypoxic cells often revert to aerobic metabolism for the
production of ATP (the Warburg effect) [73,74] to maintain enough
energy to continue to thrive. Interleukin IL-17 is the major effector
cytokine of TH17 cells, a subtype of adaptive immunity cells. Tumors
resistant to treatment with antibodies to VEGF were rendered sensitive
in IL-17 receptor (IL-17R)-knockout hosts deﬁcient in TH17 effector
function. Furthermore, pharmacological blockade of TH17 cell function
sensitized resistant tumors to therapy with antibodies to VEGF. These
ﬁndings indicate that IL-17 promotes tumor resistance to VEGF
inhibition, suggesting that immunomodulatory strategies could improve
the efﬁcacy of anti-angiogenic therapy [75].
Overall, the tumor microenvironment can often provide a physical
and chemical network to allow the cancer cells to survive, proliferate,
and avoid cytotoxic agents. Thus, the blockage of cancer speciﬁc
extracellular matrix protein synthesis may lead to physiological
normalization of tumor tissue structure (vascular supply) and potential
reduction of resistance to conventional chemotherapy [76,77].
Modulation of various aspects of the tumor microenvironment may
prove to be an effective strategy in the destruction of the tumor support
system that allows cancer cells to survive.
4. Evaluation of nano-drug deliverymechanisms and their potential
moieties to treat MDR cancers
4.1. Passive transport and enhanced permeability and retention (EPR) effect
A number of different nanoparticles rely on the characteristics of the
tumor for drug accumulation and thus are considered to be passively
targeted. During tumor formation, rapid and imperfect angiogenesis
occurs, creating leaky blood vessels. Further, these tumors have
dysfunctional lymphatic drainage, which also results in drug
accumulation [78]. Nanoparticles take advantage of this EPR effect,
which allows these drug carriers to accumulate inside of the tumor.
However, it has been shown that there are inconsistencies in vascular
pore size both within a tumor and between different tumor types.
This can lead to an unpredictable accumulation of the drug in only
certain areas of the tumor, or possibly not at all. The EPR effect is
also inﬂuenced by the surrounding stroma, the location and size of
the tumor, the amount of inﬁltration by macrophages (which can
internalize liposomes resulting in macrophage toxicity), patient
characteristics such as age and gender, and additional medications.
Currently, the available clinical data relate to passively targeted
liposomes, but a number of actively targeting nanoparticles are also in
clinical development [79]. Due to the unpredictability of the EPR effect
and the ineffectiveness against non-solid tumors such as leukemia, a
greater focus on targeted therapy may be necessary in the future.
Despite the fact that the EPR-based targeting is only passive and may
be unpredictable, nanodrugs consistently have a better accumulation
within a tumor than free drugs including Paclitaxel [80], rapamycin
[81], thiostrepton [8], Doxorubicin [82], and Salinomycin [83], among
countless others.
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Fig. 5. Representative example of the complexity of the tumor microenvironment and its interactions with tumor cells.
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time
The conjugation of polyethylene glycol (PEG) to nanoparticles has
been shown to increase circulation time in vivo. A number of potential
mechanisms have been proposed to explain this observation although it
is still not completely understood. These mechanisms include: reduced
opsonization, promotion of the adsorption of proteins which may mask
the particle (dysopsonization), aggregation prevention, steric hindrance
to block the binding of reticuloendothelial system (RES) cells, which are
responsible for the clearance of nanoparticles, and stabilization of lipid
layers. Recently, Gottstein et al. used a mathematical model combined
with high throughput ﬂow cytometry and quantitative confocal
microscopy to conﬁrm a general trend of reduced internalization by RES
cells [84]. Since chemotherapeutic agents are typically low in molecular
weight, they are rapidly cleared from the body and often suffer from a
short half-life in blood. The need to improve drug accumulation in the
tumor site during treatment, especially for resistant tumors, relies heavily
on the stability of the drug in plasma, which is greatly increased with
nanomedicines. The ﬁrst PEGylated nanoparticle approved in the United
States and Europe is liposomal Doxorubicin (Doxil®/Caelyx® [PLD]) for
the treatment of Kaposi's sarcoma [85], recurrent ovarian cancer [86]
and multiple myeloma [87], with additional clinical trials ongoing for
metastatic breast [88], and hormone refractory prostate cancer [89]. The
conjugation of PEG to liposomes [1,90], polymer-based nanoparticles
and micelles [7,91], dendrimers [92], gold nanoparticles [11,13], and
superparamagnetic iron oxide [93] is now a common practice to improve
circulation time and avoid clearance. However, it is important to note that
there are still possible negative side effects including an immunological
response through complement activation, toxicity of side products, and
possible accumulation of PEG due to its non-biodegradability [94].
4.3. Active targeting agents to increase drug accumulation and overcome
MDR
4.3.1. Antibodies and their fragments speciﬁcally target cancer cells
A number of mAbs have been approved for the treatment of various
cancers including rituximab (Rituxan) for non-Hodgkin's lymphoma[95], the anti-HER2 trastuzumab (Herceptin) [96], the anti-VEGF
bevacizumab (Avastin) to inhibit angiogenesis [97], and the anti-EGFR
cetuximab [98], along with many others that are either already
approved or are undergoing clinical trials. These therapeutic antibodies,
as well as targeting antibodies such as 2C5 [2] and anti-transferrin
receptor mAbs [99–101], can be conjugated to various nanoparticles
to improve efﬁcacy and increase binding afﬁnity to the cancer cells.
The increased speciﬁcity results in a higher accumulation of drugwithin
the tumor rather than other vital organs, reducing toxicity and making
the drug better equipped to overcome MDR. The use of whole
antibodies is considered advantageous due to the presence of two
binding sites and increased stability during long-term storage.
However, the intact Fc domain may also bind to the Fc receptors on
normal cells causing an activated signaling cascade that may result in
increased immunogenicity [102]. Thus, the speciﬁcity of the targeting/
therapeutic antibody is crucial to avoid toxicity to normal tissue.
4.3.2. Nucleic acid aptamers (single strandedDNA or RNA oligonucleotides)
Aptamers are nucleic acid ligands that can bind with high afﬁnity
and speciﬁcity. Strategies have been developed to isolate and enrich
cancer cell-speciﬁc internalizing aptamers, and they have been
successfully conjugated to a number of different nanoparticles. They
are considered to have high afﬁnity and low immunogenicity but
some drawbacks include lack of ﬂexibility, length (typically 75–100
nucleotides), and in vivo nuclease stability. Currently, all nanoparticles
using aptamers as target agents are still in the preclinical phase [103].
4.3.3. Receptor ligands (peptides) as non-immunogenic targeting agents
The conjugation of peptides as targeting agents is favorable due to
their small size, the ease of synthesis, and their typical non-
immunogenicity. Tumor homing peptides include those with an RGD
sequence motif, i.e. a binding motif for integrins, such as αvβ3, which
is speciﬁcally expressed on tumor endothelia [104], and those that
have a form of aminopeptidase N (CD13) that binds peptides with the
NGR motif. Delivery of TNFα using both RGD and NGR peptides has
shown to decrease the effective dose by up to 1000-fold [105] and an
NGR-hTNF peptide is currently in phase III clinical trials [106]. Further,
these peptides may not only play a role in homing but in tumor-
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from blood vessels and can activate a tissue-speciﬁc transport pathway
[105], which is a big advantage in treating resistant tumors. Despite
their potential, it is important to note that peptides such as RGD can
bind to other integrins on normal tissue making speciﬁcity of the
peptide a crucial consideration [102]. Moreover, most peptides on
nanoconjugates rely on polyvalency to achieve optimal cell binding.
Polyvalency depends on geometry and density of targeted receptors
that are, however, difﬁcult to mirror on nanoparticles [87].
4.4. Enhanced endosomal escape to improve efﬁcacy of the drug once
internalized
Nanoparticles have been shown to be internalized through clathrin-
dependent and clathrin-independent endocytosis depending on the cell
type and the composition of the cell surface. The addition of antibodies
and targeting ligands is aimed at increasing receptor-mediated
endocytosis. However, once inside the cell, these nanoparticles may
either fuse with lysosomes or be recycled back to the cell surface,
making endosome escape a key limitation [107]. To overcome this
barrier, Pittella et al. synthesized a nanocarrier system composed of
calciumphosphate and comprising PEG and charge-conversion polymer
(CCP) to deliver siRNA. The PEG-CCP is an endosomal escape unit that
induces endosomal membrane destabilization by producing polycation
through degradation of the ﬂanking cis-aconitylamide of CCD in the
acidic endosome environment. Rapid endosomal escape was conﬁrmed
using confocal laser scanning microscopy, and ~80% VEGF mRNA
knockdown in pancreatic cancer cells was achieved [108]. Ding et al.
also took advantage of the acidic endosome environment and
conjugated H2N-Leu-Leu-Leu-OH (LLL) to our polymalic acid based
nanopolymer (P/LLL). At physiological pH 7.4, the P/LLL conjugates
were inactive but at pH 5–5.5 (the range of acidiﬁcation in late
endosomes and lysosomes), activity was upregulated and membrane
disruption allowed for endosomal escape of the nanoconjugate [76].
Biological activity of nanoparticles often relies heavily on the ability to
escape the endosome and enter the cytosol, making endosome escape
units an area not to be overlooked.
5. Speciﬁc resistance mechanisms overcome by nanomedicine
5.1. Evasion and down-regulation of drug efﬂux pumps to treat MDR
tumors
It is agreed that chemotherapeutics bound as nanoconjugates or
encapsulated into nanoparticles evade the capture of ABC drug efﬂux
pumps. This is so because the chemically bound or encapsulated drugs
are not physically recognized as substrates by the ABC efﬂux systems.
After crossing the efﬂux containing membranes on endosomal delivery
pathway, the free chemotherapeutics are released into the perinuclear
region of the cytoplasm and can unfold their activities. Alternate
methods of entry into the target cell uses virus-derived TAT peptides,
non-speciﬁc cell penetrating peptides that interact strongly with
phosphate head groups of phospholipids at both sides of the lipid
bilayer, followed by insertion of charged side chains that form a
transient pore, which allows the translocation of the TAT peptides.
Small molecules attached to peptides can be internalized through this
mechanism, whereas TAT-polymer conjugate can be taken up through
energy-dependent endocytosis or macropinocytosis [18]. A novel
polymericmicelle consisting of Doxorubicin and two block copolymers,
one conjugated to TAT, has been produced. The micelle surface hides
the TAT during circulation and only exposes it at a slightly acidic
tumor extracellular pH to allow for TAT-induced internalization into
cancerous cells. The micelle core then disintegrates in the early
endosomal pHof the cells to release Doxorubicin. Further, the ionization
of the block copolymers aids in disrupting the endosomal membrane,
allowing the drug to accumulate in the cytosol. Regression of tumorswas apparent in xenograft models of human ovarian tumor drug-
resistant A2780/AD, human breast tumor MCF-7, human lung tumor
A549, and human epidermoid tumor KB using this drug as a non-
speciﬁc targeting agent [109]. Human gliomas are also known to have
enhanced activity of drug efﬂux pumps. The multidrug-resistance-
associated protein (MRP), an ABC membrane transporter not
dependent on P-glycoprotein, is highly expressed in the severely drug
resistant glioma cell line T98G (4.5 fold higher than drug-sensitive
U87MG) [110]. Currently, the most effective strategy to treat glial cells
is temozolomide (TMZ), a pro-drug releasing a DNA alkylating agent,
combinedwith radiation. However, TMZ is toxic, has severe side effects,
and frequently encounters tumor drug resistance. Free TMZ, which has
a short half-life of 1.8 h, proved to be ineffective in vitro against the
resistant T98G cell line, as well as two human breast cancer lines
MDA-MB-231 and MDA-MB-468, although U87MG was sensitive. A
multifunctional targetable nanoconjugate of TMZ hydrazide was
synthesized using a poly (β-L-malic acid) platform conjugated with
the targeting mAb to human transferrin receptor (TfR) for receptor-
mediated endocytosis, LLL for pH-dependent endosomal membrane
disruption, and PEG for protection. The conjugated TMZ had an
increased half-life of 5–7 h. Delivery of PMLA-TMZ conjugate to T98G,
MDA-MB-231, and MDA-MB-468 was able to effectively overcome the
resistance of free TMZ and signiﬁcantly reduced cell viability as shown
in Fig. 6. The greater drug accumulation was due to the avoidance of
the drug efﬂux pump mechanism via receptor-mediated endocytosis
[111]. In addition to T98G, the human glioblastoma cell line U251 is
known to have MDR due to the high expression of P-glycoprotein and
other ABC transporters. Another version of PMLA containing PEG, with
Doxorubicin conjugated via pH-sensitive hydrazone linkage, was able
to effectively inhibit growth of U251 more than Doxorubicin alone
due to the modiﬁed drug uptake mechanism that evaded drug efﬂux
pumps [112].
Direct targeting of the upregulated P-glycoprotein while simul-
taneously treating with anti-cancer therapeutics is yet another strategy
that nanomedicine can employ. The use of P-glycoproteins inhibitors is
an attractiveﬁeld but has unfortunately resulted in numerous failures in
the clinic to date. Inhibitors including verapamil, a calcium channel
blocker, and cyclosporine, an immunosuppressant, are actually substrates
for P-glycoprotein and compete for efﬂux with the chemotherapeutic
drugs. Their lack of speciﬁcity requires a large dose to achieve clinical
inhibition and thus results in toxicity. Numerous modiﬁcations of these
inhibitors have appeared as promising candidates, but clinical trials
continue to fail [113]. However, the use of these molecules in relation
to nanomedicines is still an attractive strategy due to increased targeting
and accumulation. For example, Wu et al. used a liposome co-
encapsulating Doxorubicin and verapamil and conjugated to transferrin,
to effectively overcome MDR in K562 leukemia cells [114]. Another
group encapsulated curcumin, known as P-glycoprotein pump inhibitor,
and Paclitaxel in a nanoemulsion of ﬂaxseed oil to effectively treat wild-
type and drug resistant SKOV3 ovarian tumor cells [115]. Further,
liposomal anti-MRP-1 and anti-Bcl2 siRNA in combination with
Doxorubicin were used to suppress pump and non-pump mediated
cellular resistance and to cause death in MDR lung cancer cells [116].
Finally, stealth liposomes containing PSC 833 (Valspodar, a cyclosporin
A analog that is more effective) and Doxorubicin were able to reverse
MDR in the Doxorubicin-resistant human breast cancer cell line T47D/
TAMR-6 [117].
5.2. Targeting cancer stem cells to overcome MDR and prevent recurrence
Cancer stem cells are more resistant to treatment and conventional
chemotherapeutics often fail to destroy them. CSC resistance is
achieved through increased Wnt/β-catenin and Notch signaling, high
levels of ATP cassette reporters, altered DNA repair mechanisms, and
slow proliferation rate [118]. A study of osteosarcoma cell lines showed
that an anti-cancer drug Salinomycin could suppress tumor cells in vitro
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signaling pathway [119]. Zhang et al. loaded Salinomycin on PEGylated
polymeric micelles to effectively target CSC (CD44+/CD24−) isolated
from breast cancer cell line MCF-7, and these micelles were more
effective than Salinomycin alone in vivo. A combination treatment
with octreotide-modiﬁed-Paclitaxel-PEG polymeric micelles was
shown to enhance the binding to somatostatin receptors, which
are enhanced in many cancers, to eradicate both tumor cells and
CSC in vivo via receptor-mediated endocytosis [83]. The knockdown of
other CSC related pathways including tissue transglutaminase (TG2)
by gene silencing using liposomal anti-TG2 siRNA combined with
gemcitabine to treat Panc-28 pancreatic cancer cells was efﬁcacious in
reducing tumor growth and preventing metastasis [120]. Additional
stem cell markers including CD44 [38,121] and CD133 [121] have
been associated with drug resistance andmay serve as potential targets
for future nanodrugs to eliminate CSCs and prevent recurrence.
5.3. Preventing the cross talk of cancer cells and their microenvironment
Prevention of the cross talk between cancer cells and supporting
stroma and vasculature, which promotes cell growth and prevents
apoptosis, is an attractive strategy for overcoming resistance to
therapy. Mature B-cell malignancies are known to interact via CXCR4
signaling, a G-coupled protein receptor, found on hematopoietic and
epithelial cancer cells. Stromal cells located in the bone marrow
microenvironment secrete stromal cell-derived factor 1 (SDF-1/
CXCL12), the ligand for CXCR4. This signaling recruits the cancer cells to
the bone marrow where they receive additional growth and drug
resistance signals. Antagonists of CXCR4 can disrupt these interactions,
forcing the leukemia cells back into circulation where they are more
susceptible to chemotherapeutic drugs [122], and may serve as crucial
additions on nanodrugs. Attempts to actually target and destroy tumor
stromal cells have also been performed to prevent their contribution to
tumor growth. Tumor-related stromal cells express high levels of
platelet-derived growth factor receptor-β (PDGFR-β). A uniquenanocarrier was made using albumin and a PDGFR-β recognizing cyclin
peptide conjugated to Doxorubicin through an acid-sensitive hydrazone
linkage. In vivo, the drug rapidly accumulated in PDGFR-β expressing
cells in C26murine colon cancer and signiﬁcantly reduced tumor growth;
free Doxorubicin was not as effective and resulted in loss of body weight
[123]. Interfering with the signaling of the microenvironment or even
potentially eliminating key stromal contributors of anti-apoptotic, pro-
growth, and pro-angiogenesis signals using a targeted nanotherapy are
promising approaches.
5.4. Modifying the immune response to improve treatment of MDR cancers
Immune response modiﬁcation can occur either through inhibition
or enhancement. Several groups have used siRNA, frequently in cationic
liposomes, to downregulate essential immune transcription factors,
proinﬂammatory cytokine production, especially TNF-α, or cellular
receptors to prevent cell activation. Both siRNA and various
nanoparticles can elicit an interferon-mediated immune response.
Therefore, it is not only the inhibitory effect of the siRNA, but also the
immunostimulatory effect of the treatment that leads to a reduction in
tumor size [124]. Using siRNAs to elicit an antitumor effect have
shown to be effective. Pertinent examples include using Bcl2-speciﬁc
siRNA with 5′-triphosphate ends against melanoma to silence Bcl2
and enhance activity of natural killer cells and interferon through innate
cell activation via Rig-1 [125]; using a toll-like receptor (TLR)9 agonist,
Stat3, siRNA synthetically linked to a CpG oligonucleotide to inhibit
expression in dendritic cells, macrophages and B cells, leading to the
activation of tumor-associated immune cells and an anti-tumor
immune response to mouse melanoma and colon cancer [126]; and
using a bifunctional siRNA complexed with PEGylated liposomes to
inhibit HPV16 E6/E7 mRNA and to activate immune response cells via
TLR7 to effectively inhibit TC-1 tumors in vivo [127]. In addition to the
use of siRNAs, other nanomedicine approaches for altering immune
response have been explored. An antibody cytokine fusion protein
consisting of the immunostimulatory cytokine interleukin-2 (IL-2)
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covalently attached to a polymalic acid (PMLA) backbone. The drug
also contained antisense oligonucleotides against α4 and β1 chains of
vascular tumor protein laminin-411 to block angiogenesis. Treatment
of immunocompetent mice bearing murine mammary tumors
expressing human HER2/neu resulted in signiﬁcant increases of IgG1
and IgG2a, indicative of a humoral (TH2) and cell-mediated (TH1)
immune response, as well as decreased tumor growth and longer
survival [128]. With the increase of resistance to a number of
therapeutics, the use of immunostimulatory drugs may prove to be
advantageous in avoiding and overcoming drug resistance in the future.Table 1
Recent progress in overcoming tumor drug resistance by using nanomedicines.
Tumor type Nanomedicines Ac
Docetaxel (DTX)-resistant human
ovarian A2780/T.
In vitro model
D-α-Tocopheryl polyethylene glycol
1000-block-poly(β-amino ester)
containing micellar nanoparticle
D-
-p
do
H460/TaxR human non-small cell
lung cancer overexpressing P-gp
In vitro model
D-α-Tocopheryl polyethylene glycol
1000 succinate containing micellar
nanoparticle
D-
po
su
(P
Human MCF7/ADR tumor on BALB/c
nude mice.
In vivo breast cancer model
Poly[bis(2-hydroxylethyl)-disulﬁde-
diacrylate-β-tetraethylenepentamine]–
polycaprolactone copolymer (PBD–PCL)
containing micelle nanoparticles
sh
PB
CD138− CD34− cells isolated from a
human U266 multiple myeloma cell line
inoculated in mice with
non-obese diabetic/severe combined
immunodeﬁciency
(NOD/SCID).
In vivomodel
Polyoxypropylene chain and oleic acid
coated iron oxide NPs
An
PT
Human lung adenocarcinoma A549-Bcl-2 cells
In vitro model
Micelleplexes siR
CAL27 cisplatin-resistant human oral cancer
cells (CAR cells),
In vitro model
PLGA nanoparticles Cu
Human breast cancer MDA-MB-231 cells
inoculated into BALB/c nu/nu mice.
Xenogeneic in vivomodel
PLGA nanoparticles conjugated to
Anti-CD133
An
GS5 glioblastoma multiforme cells (obtained
from human U87GM cells enriched by stem
cells) injected intracranially in rats.
In vivomodel
PGLA nanoparticles
Treatment by convection-enhanced
delivery (CED)
Di
Rat F98 glioblastoma inoculated on Fischer
344 rats.
Orthotopic syngeneic in vivomodel
PGLA-chitosan Ca
O(
Chemotherapy- and
antiandrogen-resistant mAR+/GPRC6A+
DU-145 human prostate carcinoma cells.
In vivomodel
Gold nanoparticles M
an
Human breast MDA-MB-231 and
MDA-MB-468 cell lines, and brain cancer
cell lines U87MG and T98G
In vitro model
Polymer–drug conjugate based on poly
(β-L-malic-acid) platform
Te
Human Lewis lung carcinoma A549 cells
subcutaneously inoculated into
C57BL/6N mice,
In vivomodel
Nanoliposomes in combination with
radiation therapy
Ci
Ra
Human SW480 Colorectal cancer.
In vitro model
Human serum albumin-based
anti-Survivin siRNA delivery in
combination with radiation therapy
An
Ra
Human melanoma cells HMV-II; Radiation
resistance under hypoxic conditions.
In vitro model
Liposomes in combination with
radiation therapy
Pi
Ra
Human U251 glioblastoma intracranially
grown in Nu/Nu rats.
In vivo model
Magnetic ferric oxide NP in combination
with radiation therapy
TR
tra
ho
(T
Ga
HMLER (shE-cadherin) human breast cancer
stem cells (BCSCs) inoculated into mice to
treat triple-negative breast cancer.
In vivo model
Multiwalled carbon nanotubes
(MWCNTs) in combination with
photothermal (laser) treatment.
Na
ta
pe
Ph6. Recent progress in overcoming tumor resistance by
using nanomedicines
Engineering of multifunctional nanodrugs demonstrates new
possibilities to overcoming drug resistance that were not possible
with conventional therapy or combination of different current cancer
treatments. Recent experimental progress in overcoming resistance by
using nanomedicines in vitro and in vivo is summarized in Table 1.
Nanocarriers can display their own anti-drug resistance activity aside
from actions by their cargo. This has been shown for α-tocopheryl
PEG1000 succinate [129,130] and poly[bis(2-hydroxylethyl)-disulﬁde-tive groups Action mechanism Ref.
α-Tocopheryl
olyethylene glycol,
cetaxel
Inhibition of P-gp to decrease DTX efﬂux;
DTX Inhibition of cell division
[133]
α-Tocopheryl
lyethylene glycol 1000
ccinate; paclitaxel
TX), ﬂuorouracil (5-FU)
Inhibition of P-glycoprotein by Tocopheryl
polyethylene glycol 1000 succinate; Inhibition of
cell division by PTX; irreversible inhibition of
thymidylate synthase; synergism of PTX/5-FU.
[140]
RNA to Survivin,
D–PCL, Doxorubicin
Inhibition of: P-glycoprotein; inhibition of
glutathione S-transferase, intercalation into DNA
[137]
ti-ABCG2 antibody,
X
Antibody blocking of ABCG2 to inhibit PTX
resistance; PTX inhibition of cell division
[138,144]
NA to BCl-2, PTX Downregulation of Bcl-2; PTX Inhibition of
cell division
[129]
rcumin, cisplatin Pt-DNA crosslinks;
MDR-1 suppression;
Triggering of Apoptosis
[131]
ti-CD133, PTX Targeting tumor initiating cells CD133+; PTX
inhibition of cell division
[134]
thiazanine iodide (DI) DI displays toxicity towards brain cancer
stem cells
[135,145]
rmustine (BCNU),
6)-benzylguanine (BG)
BCNU for DNA alkylating and crosslinking;
BG for inhibition of O(6)-methylguanine-DNA-
methyl transferase (MGMT)
[130]
ultiple α-Bic- and β-Bic
tiandrogens
Multivalent binding to androgen receptor and to
G-protein coupled receptor (GPRC6A); The
antiandrogens inhibit binding of androgen
[143,146]
mozolomide (TMZ) TMX is a DNA alkylating agent preventing cell
division
[110]
splatin (CDDP),
diation therapy
Cisplatin alkylating and crosslinking DNA;
Sensation to radiation lesions
[136]
ti-Survivin siRNA;
diation therapy
Knocking down of Survivin promotes apoptosis [141]
monidazole (Pmz);
diation therapy
DNA fragmentation and crosslinking sensitizes for
radiation damage
[142]
IAL, a type-II
nsmembrane
motrimeric protein
NF gene superfamily)
mma irradiation
Radiation sensitizes for TRAIL induced apoptosis;
Sensitization of TRIAL by conjugation to the ferric
oxide nanoparticle
[139]
notubes without active
rgeting but with speciﬁc
rmeation into BCSCs;
otothermal treatment.
Thermal therapy promotes rapid MWCNT
membrane permeabilization resulting in necrosis
of BCSCs and differentiated cancer cells.
[132,147]
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[131] for the inhibition of efﬂux-dependent mechanisms or carbon
nanotubes for membrane permeabilization and sensitization to photo
thermal therapy [132]. Drug efﬂux systems [129–131,133–136],
resistance due to presence of CSC [132,137–139], DNA damage/repair
[136,140–142], apoptosis signaling pathways [139,141,143], resistance
against radiation therapy [136,139,141,142], and resistance against
thermal treatment [142] are being studied in vitro and in vivo as
targets for nanomedicines in order to develop the best treatment
regimens. Diverse functions and multiple effects are typical for the
composition and design of multifunctional nanomedicines. Active
cargo, such as siRNA, and antibodies speciﬁcally inhibit synthesis or
function of proteins, which are key players in resistance mechanisms
[134,135,137]. Various chemotherapeutic drugs when delivered as a
nanoparticle cargo can bypass drug resistance resulting in higher
toxicity for tumor cells with lower toxicity to normal tissues. Examples
of the drugs used as part of nanoparticles and nanoconjugates include
taxanes [129,130,134,135,137], 5-ﬂuorouracil [140], dithiazanine
iodide [135], carmustin, cisplatin, pimonidazole [130,136,142], effectors
of enzyme activity [130,140] and signaling, such as antiandrogens and
TRAIL [139,143]. Nanoparticles and their cargoes have been found to
be sensitizers for killing of differentiated cancer cells and CSCs by
radiation therapy [136,139,141,142] and laser hyperthermal therapy
[132]. It can be hypothesized that cancer therapy using nanodrugs
alone or in combination with radiation/hyperthermia can overcome
resistance by delivery of one or several nonrelated therapeutic agents,
and modern nanomedicines can afford to deliver all these moieties
into the cancer cells.
7. Conclusion and future direction
The lifetime probability of developing cancer for men (45%) and
women (38%) is startlingly high and accounts for 1 in 4 deaths in the
United States [148]. Despite our vast expanse of knowledge regarding
the disease, it continues to progress faster than we can keep up with. A
number of underlying mechanisms regarding progression, metastasis,
and invasion have been elucidated at both cellular and molecular levels,
which serve as promising traits to focus on for nanodrug therapy when
surgery, radiation, and chemotherapy are insufﬁcient. Despite these
advances that target signaling mechanisms and upregulated genes and
proteins, drug resistance remains a key feature of cancer cells and is
often acquired even after an initial positive response. Nanomedicines
that have increased circulation time, precise multiple targeting
mechanisms, enhanced drug accumulation at the tumor site, delivered
into the cytoplasm and/or nuclei of cancer cells, and have the ability to
carry combinations of therapeutic payloads are attractive treatment
options in overcoming MDR. Numerous unique nanodrugs have
been created and researched extensively, and are already in clinical
development. As additional discoveries and optimizations are achieved,
the superiority of nanomedicines over current treatment options and
free drugs will continue to increase for the efﬁcient eradication of
drug-resistant cancers.
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